Johnson & Johnson (JNJ)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell
$151.00
Buy
$151.10
$1.72 (+1.15%)
Prices updated at 17 May 2025, 00:58 EDT
| Prices minimum 15 mins delay
Prices in USD
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
---|---|---|
85,159m | 88,821m | |
58,606m | 61,350m | |
23,409m | 22,149m | |
27.49 | 24.94 | |
35,153m | 14,066m | |
23,320m | 24,781m | |
Sales, General and administrative | 20,112m | 21,969m |
Interest expenses | 772m | 755m |
Provision for income taxes | 1,736m | 2,621m |
Operating expenses | 35,197m | 39,201m |
Income before taxes | 15,062m | 16,687m |
Net income available to common shareholders | 35,153m | 14,066m |
13.88 | 5.84 | |
Net interest income | 489m | 577m |
Advertising and promotion | - | - |
Net investment income, net | - | - |
Realised capital gains (losses), net | - | - |
Total benefits, claims and expenses | - | - |
Earnings per share (diluted) | 13.72 | 5.79 |
Free cash flow per share | 6.0161 | 7.8293 |
Book value/share | 29.5911 | 29.1484 |
Debt equity ratio | 0.37632 | 0.428745 |
Balance sheet
Year | 2023 | 2024 |
---|---|---|
Current assets | 53,495m | 55,893m |
Current liabilities | 46,282m | 50,321m |
Total capital | 94,655m | 102,141m |
Total debt | 29,332m | 36,634m |
Total equity | 68,774m | 71,490m |
Total non current liabilities | - | - |
Loans | 25,881m | 30,651m |
Total assets | 167,558m | 180,104m |
Total liabilities | - | - |
Cash and cash equivalents | 21,859m | 24,105m |
Common stock | 2,407m | 2,407m |
Cash flow
Year | 2023 | 2024 |
---|---|---|
Cash at beginning of period | 14,127m | 21,859m |
Cash dividends paid | -11,770m | -11,823m |
17,778m | 18,059m | |
Investments (gains) losses | 878m | -18,599m |
21,859m | 24,105m | |
Net income | - | - |
22,791m | 24,266m | |
-5,013m | -6,207m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.